BB

BB Biotech is a Switzerland-based publicly listed investment company focused on biotechnology. Rather than developing its own drug pipeline, it invests in publicly traded biotech companies that are developing and commercializing innovative therapies for serious diseases with significant unmet medical need. The company is managed by Bellevue Asset Management and uses a long-term, research-intensive, conviction-driven investment approach grounded in scientific and fundamental analysis. Its portfolio generally spans biotechnology companies across areas such as oncology, infectious disease, metabolic disease, autoimmune disease, and neurology. For a biotech analyst, BB Biotech is best understood as a specialist biotech investment vehicle rather than an operating drug developer.